Medical
Defactinib for Mesothelioma: 344-Patient COMMAND Trial and What FAK Inhibitors Mean in 2026
David Foster
March 20, 2026
Defactinib (VS-6063) FAK inhibitor showed HR 0.56 in merlin-low mesothelioma patients. Learn about COMMAND trial results, biomarkers, and combination trials.
12 min read 7 FAQs
Read